| Revenue growth | Q2 +16% YoY; H1 +16% YoY |
|---|---|
| Margins | Q2 EBITDA 27.2%, +180bps; PAT margin +290bps |
| Demand visibility | Sustained demand momentum; volume-led growth |
| Management confidence | Claims H1 delivery ahead of guidance |
Growth
Q2 revenue +16%, EBITDA +24%, PAT +43% YoY. H1 revenue +16%, EBITDA +25%, PAT +35%. Growth is volume-led, with no price increases.
Outlook
No numeric forward guidance given. Stated targets are ESG goals such as net zero Scope 1 and 2 by FY43 and B2C NPS above 90 by FY28.
Risks
No explicit headwinds disclosed. Revenue per patient rose only 6% with no price increase, so growth depends on volumes.
Last quarter's promises, checked
Delivered
- Revenue growth 14–15% ex-price guided → Q2 +16%, H1 +16% (= BEAT)
- Specialty/TruHealth growth above company rate → +20% vs company +16% (= BEAT)
Partly delivered
- EBITDA margin 24.4% → 27–28% within 2–3 yrs → Q2 27.2% (= PARTIAL; lower bound hit in one quarter, horizon untested)
Investor Presentation filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹568.70
- Market cap
- ₹11,798 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 58.5×Sector 53.7×
- Promoter holding
- 47.82%-1.04% QoQ
- FII holding
- 11.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Dividend
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 26-27. The record date is 9 November 2026.
Metropolis Healthcare Results Update
Metropolis Healthcare posted Q2 FY27 revenue up 16% to ₹497 crore and PAT up 43% to ₹75 crore. Board declared a ₹1 per share interim dividend.
Metropolis Healthcare Q2 FY27 Results: Net Profit ₹75.5 Cr, Up 42.7% YoY
Metropolis Healthcare Ltd reported revenue from operations of ₹496.8 Cr (+15.8% YoY) and net profit of ₹75.5 Cr (+42.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹75.5 Cr · +42.7% YoY
Metropolis Healthcare Employee Stock Options
Metropolis Healthcare granted 24,060 RSUs and 3,58,920 ESOPs under its 2025 plans, and allotted 65,600 shares under its RSU Plan 2020.
Metropolis Healthcare Board Meeting Date
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Metropolis Healthcare Other Announcement
Metropolis Healthcare Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides details on the company's equity share distribution.